SuperworthCocrystal Pharma EPS COCP
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$0.77
- Latest quarter, Q2 FY26
- −$0.23
- Fiscal year 2025
- −$0.80
Cocrystal Pharma's earnings per share was −$0.77 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.23.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.80 | n/a |
| FY2024 | −$1.73 | n/a |
| FY2023 | −$1.90 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$1.89 | n/a |
| FY2020 | −$2.28 | n/a |
| FY2019 | −$17.16 | n/a |
| FY2018 | −$19.80 | n/a |
| FY2017 | −$0.96 | n/a |
| FY2016 | −$40.80 | n/a |
| FY2015 | −$39.60 | n/a |
| FY2014 | −$2095.20 | n/a |
| FY2013 | −$25.20 | n/a |
| FY2012 | −$46.80 | n/a |
| FY2011 | −$28.80 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.23 | n/a | −$0.77 | |
| Q1 FY26 | −$0.17 | n/a | −$0.74 | |
| Q4 FY25 | −$0.18 | n/a | −$0.80 | |
| Q3 FY25 | −$0.19 | n/a | −$0.94 | |
| Q2 FY25 | −$0.20 | n/a | −$1.24 | |
| Q1 FY25 | −$0.23 | n/a | −$1.57 | |
| Q4 FY24 | −$0.32 | n/a | −$1.73 | |
| Q3 FY24 | −$0.49 | n/a | −$1.85 | |
| Q2 FY24 | −$0.53 | n/a | −$1.77 | |
| Q1 FY24 | −$0.39 | n/a | −$1.65 | |
| Q4 FY23 | −$0.44 | n/a | −$1.90 | |
| Q3 FY23 | −$0.41 | n/a | −$2.01 |
Against its peers
Companies in Drug Manufacturers - General nearest Cocrystal Pharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| COCPCocrystal Pharma | −$0.77 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cocrystal Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.